Brand Name

Aqneursa

Generic Name
Levacetylleucine
View Brand Information
FDA approval date: September 24, 2024
Form: Granule

What is Aqneursa (Levacetylleucine)?

AQNEURSA™ is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and pediatric patients weighing ≥15 kg. AQNEURSA is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and pediatric patients weighing ≥15 kg.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses.
Neurofilament light chain (NfL) as a surrogate outcome measure for GM2 gangliosidoses.
Journal: Journal of neurology
Published: April 27, 2026
N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C.
N-acetyl-L-leucine normalizes Transcription Factor EB activity by stereospecific bidirectional modulation in a HeLa cell model of Niemann-Pick disease type C.
Journal: PloS one
Published: March 20, 2026
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.
Safety and efficacy of levacetylleucine in ataxia-telangiectasia: a phase 3, randomised, double-blind, placebo-controlled crossover trial.
Journal: The Lancet. Neurology
Published: March 15, 2026
View All Latest Advances